We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 39

Moneytree report shows increased life sciences investments in Q1 2011
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall


U.S. biotech sector shows IPO gains in 2013
  • Shook Hardy & Bacon LLP
  • USA
  • June 6 2013

According to Reuters, 14 biotech companies have gone public so far in 2013, marking a possible turnaround for the sector with a rising stock market


Pharma and biotech stocks rise, M&A and IPO values strong, licensing deals
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Market analysts commenting on the dramatic rise in the Nasdaq Biotech Index (up 27) and the Dow Jones US Pharma Index (up 21) in the first half of


New program to provide accelerated “speed-to-market” for medical device entrepreneurs
  • Shook Hardy & Bacon LLP
  • USA
  • March 1 2012

The nonprofit Memphis Bioworks Foundation and Innova, a pre-seed, seed and early-stage investor, have announced a program designed to help entrepreneurs bring medical device products and companies to market


North Carolina life sciences companies attract more than $1.1 billion in investments, grants
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

After conducting its yearly survey of media reports, a North Carolina trade association has announced that life sciences companies brought in more than $1.1 billion in investments and grants to the state in the 12 months ending April 25, 2011, representing a 25 percent increase over the 12-month period ending April 2010


Synageva announces $25 million for rare disease product development
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

Synageva BioPharma Corp. has announced an additional $25 million in private equity financing to support therapeutic product development


Biotech companies struggling in public markets
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand


Barbados launches biotech initiative designed to shorten R&D process
  • Shook Hardy & Bacon LLP
  • Barbados
  • December 16 2010

The Barbados government has recently launched two initiatives to attract biotech companies to the island nation


Israeli biotechnology startups seek partnerships in Ohio
  • Shook Hardy & Bacon LLP
  • USA
  • December 16 2010

Israeli biotechnology companies are reportedly heading to Ohio because of state incentives and a venture capital fund focused on investing in Israel


Quebec establishes new venture capital fund to invest in biotech research
  • Shook Hardy & Bacon LLP
  • Canada
  • February 24 2011

Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research